Amit M Oza, BSc, MD, MBBS, FRCPC

Dr. Amit Oza is Head of the Division of Medical Oncology & Hematology, and Medical Director of the Cancer Clinical Research Unit at Princess Margaret (PM) Cancer Centre. He is also co-Director of the Drug Development Program at PM Cancer Centre, Scientist at the Ontario Cancer Institute, and Professor of Medicine at University of Toronto. Dr. Oza has been PI and co-investigator in >100 phase I, II and III trials for gynecological cancer and advanced colorectal malignancies. He is the past co-chair of the National Cancer Institute Gynecologic Cancer Steering Committee, and Executive Member of the international Gynecologic Cancer InterGroup. Under his direction, the gynecology group is one of the largest ovarian cancer (OC) clinical trials groups consistently accruing >30% of all patients seen onto clinical trials (>120/yr) at PM Cancer Centre. Under his direction the group has participated or led seminal studies in gynecologic cancers that have led to the approval or use of targeted agents such as PARP inhibitors (olaparib, niraparib) and anti-angiogenic agents (bevacizumab) internationally. Since 2011, he has obtained >$36.9M in peer-reviewed funding and has published >180 articles (all types) in journals, including the New England Journal of Medicine (IF=53); Lancet Oncology (IF=16), and the Journal of Clinical Oncology (IF=16.4).

Ann Oncol. 2016 Dec 19;:
Wilson MK, Pujade-Lauraine E, Aoki D, Mirza MR, Lorusso D, Oza AM, du Bois A, Vergote I, Reuss A, Bacon M, Friedlander M, Rincon D, Joly F, Chang SJ, Ferrero AM, Edmondson RJ, Wimberger P, Maenpaa J, Gaffney D, Zhang R, Okamoto A, Stuart G, Ochiai K,...
J Clin Oncol. 2009 May 20;27(15_suppl):5576
Welch S, Mackay HJ, Hirte H, Fleming GF, Morgan R, Wang L, Blattler C, Ivy SP, Oza AM
J Clin Oncol. 2009 May 20;27(15_suppl):5591
Townsley C, Hirte H, Hoskins P, Buckanovich R, Mackay H, Welch S, Wang L, Polintan R, Chen A, Oza AM
J Clin Oncol. 2009 May 20;27(15_suppl):1133
Taylor SK, Chia S, Dent S, Clemons M, Grenci P, Wang L, Oza AM, Ivy P, Pritchard K, Leighl N
J Clin Oncol. 2009 May 20;27(15_suppl):3558
Oza AM, Kollmannsberger C, NCIC Clinical Trials Group, Hirte H, Welch S, Siu L, Mazurka J, Sederias J, Doyle LA, Eisenhauer E
J Clin Oncol. 2009 May 20;27(15_suppl):3510
Schellens JH, Leijen S, Shapiro GI, Pavlick AC, Tibes R, O'Day SJ, Demuth T, Viscusi J, Xu Y, Oza AM
J Clin Oncol. 2009 May 20;27(15_suppl):e15126
Mak E, Townsley C, Buckman R, Chen E, Lopez L, Wang L, Moore M, Oza AM
Curr Opin Obstet Gynecol. 2016 Dec 09;
Lee YC, Lheureux S, Oza AM
Lancet Oncol. 2016 Nov 28;:
Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding...
Genome Med. 2016 Oct 25;8(1):109
Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, Chen EX, Krzyzanowska MK, Dhani N, Joshua AM, Tsao MS, Serra S, Clarke B, Roehrl MH, Zhang T, Sukhai MA, Califaretti N, Trinkaus M, Shaw P, van der Kwast T, Wang L, Virtanen C, Kim RH,...

Pages


 

Co-director, Robert and Maggie Bras and Family Drug Development Program​
Professor, Department of Medicine, University of Toronto
Head, Department of Medical Oncology & Hematology